All peptides.
16 compounds tracked · every vendor, every price.

15-amino-acid peptide derived from a protective protein in gastric juice. Most-researched peptide in the vendor market.

Synthetic fragment of thymosin beta-4. Actively researched for soft-tissue repair.

ACTH(4-10) analog. Investigated for cognitive and neuroprotective effects.

Russian heptapeptide derived from tuftsin. Anxiolytic/nootropic research.

Gly-His-Lys copper complex. Researched for skin repair and mitochondrial function.

Ala-Glu-Asp-Gly tetrapeptide. Researched for circadian and telomere biology.

N-terminally acetylated 28-residue peptide derived from prothymosin alpha. Researched for T-cell maturation pathways. Marketed in some countries as Zadaxin (Italy, Mexico, China) under prescription; research-peptide formulations are not approved for human therapeutic use.

GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.

Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.

Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.

Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.

Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.

Long-acting amylin-receptor agonist (AM833 / NNC0174-0833) developed by Novo Nordisk, studied alone and in the CagriSema combination; not approved as a medicine anywhere and not for human therapeutic use.

GLP-1 receptor agonist, FDA- and EMA-approved as Ozempic, Wegovy and Rybelsus. Research-vial semaglutide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.

Delta sleep-inducing peptide — 9-residue neuropeptide first isolated from cerebral venous blood during low-frequency sleep induction. Researched for sleep–wake cycle mechanisms; not approved for human therapeutic use anywhere.

Cyclic melanocortin-receptor agonist derived from α-MSH. The active molecule in Vyleesi (FDA-approved 2019, prescription-only for HSDD); research-peptide formulations are sold under research-use-only labelling and are not approved for human therapeutic use.